|
Decision 848/2024 |
||
|---|---|---|
| File (PDF) | Decision 848/2024 | |
| Date of Issuance of Decision | May 13th, 2024 | |
| Issue Number of Government Gazette | ||
| Relevant Market |
1. The private general hospital market |
|
| Subject of the Decision | Clearance decision on the notified concentration, pursuant to articles 5-10 of Law 3959/2011, concerning the acquisition of joint control by the companies “STRIX ASSET MANAGEMENT LTD” and “FARALLON CAPITAL MANAGEMENT L.L.C.” over “EUROMEDICA HEALTHCARE SERVICES S.A.”, within the meaning of Article 5 of Law 3959/2011 | |
| Legal Framework |
Article 6 of Law 3959/2011 |
|
|
Operative part of the Decision |
The Hellenic Competition Commission (HCC), in Chamber, unanimously approved, pursuant to Art. 8(3) of Greek Law 3959/2011, the notified concentration (under ref. no 10180/29.12.2023) concerning the acquisition of joint control by the companies “STRIX ASSET MANAGEMENT LTD” and “FARALLON CAPITAL MANAGEMENT L.L.C.” over “EUROMEDICA HEALTHCARE SERVICES S.A.”, as this concentration, although falling within the scope of article 6(1) of the Greek Law 3959/2011, as in force, does not raise serious concerns regarding its compatibility with competition rules in the individual markets concerned. | |
| Company(ies) concerned |
1. “STRIX ASSET MANAGEMENT LTD” The concentration consists in the acquisition by the company “STRIX ASSET MANAGEMENT LTD” of a 29.35% shareholding in the target company's “EUROMEDICA HEALTHCARE SERVICES S.A.” share capital, through “STRIX HOLDINGS ΙΙ L.P.”, a limited liability special purpose vehicle. |
|
| Summary of Decision |
There are no affected markets at a horizontal and/or vertical level in the concentration considered, as the following statutory criteria are not cumulatively met in any relevant market: a) activity of at least two (2) of the parties to the concentration and a combined market share of at least 15% (regarding the horizontally affected markets) or b) activity of at least one of the parties to the concentration and a combined market share of at least 25% (regarding the vertically affected markets). In this respect, according to the evidence in the case file, the concentration is not expected to give rise to any conglomerate effects. |
|
| Judicial Means | - | |
